Literature DB >> 2984120

Cyclic guanosine monophosphate mediates vascular relaxation induced by atrial natriuretic factor.

E H Ohlstein, B A Berkowitz.   

Abstract

The biochemical mechanism of action of synthetic atrial natriuretic factor (atriopeptin II) was studied in vascular smooth muscle of the rabbit thoracic aorta. Atriopeptin II caused a time-dependent and concentration-dependent increase in tissue levels of cyclic guanosine monophosphate that corresponded in these same tissues with vascular relaxation. The elevation of arterial cyclic guanosine monophosphate levels preceded the onset of vascular relaxation. Atriopeptin II did not alter vascular levels of cyclic adenosine monophosphate. The presence of a functionally intact vascular endothelium was not necessary for atriopeptin II to elicit vascular relaxation. Atriopeptin II-induced vascular relaxation and elevation of cyclic guanosine monophosphate levels were inhibited by the guanylate cyclase inhibitor methylene blue. These data suggest cyclic guanosine monophosphate mediates vascular relaxation produced by atriopeptin II.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984120     DOI: 10.1161/01.hyp.7.2.306

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

1.  Effects of atrionatriuretic factor on Ca2+ current and Cai-independent transient outward K+ current in human atrial cells.

Authors:  B Le Grand; E Deroubaix; J P Couétil; E Coraboeuf
Journal:  Pflugers Arch       Date:  1992-08       Impact factor: 3.657

2.  Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.

Authors:  G M Pitari; M D Di Guglielmo; J Park; S Schulz; S A Waldman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 3.  Biologically active atrial peptides.

Authors:  B J Ballerman; B M Brenner
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

4.  Mechanism of vasodilation induced by alpha-human atrial natriuretic polypeptide in rabbit and guinea-pig renal arteries.

Authors:  K Fujii; T Ishimatsu; H Kuriyama
Journal:  J Physiol       Date:  1986-08       Impact factor: 5.182

5.  Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man.

Authors:  T Fujita; Y Ito; H Noda; Y Sato; K Ando; K Kangawa; H Matsuo
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

6.  Physiologic regulation of atrial natriuretic peptide receptors in rat renal glomeruli.

Authors:  B J Ballermann; R L Hoover; M J Karnovsky; B M Brenner
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

7.  Dissociation of natriuresis and diuresis and heterogeneity of the effector system of atrial natriuretic factor in rats.

Authors:  R C Willenbrock; J Tremblay; R Garcia; P Hamet
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

8.  Effects of atrial natriuretic polypeptide and organic nitrates on levels of relaxation and cyclic nucleotide of canine coronary artery with and without endothelial injury.

Authors:  H Nakagawa; K Okumura; H Hashimoto; T Ito; K Ogawa; T Satake
Journal:  Heart Vessels       Date:  1988       Impact factor: 2.037

9.  Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts.

Authors:  Hirohisa Okawa; Hitoshi Horimoto; Shigetoshi Mieno; Yukiya Nomura; Masataka Yoshida; Sasaki Shinjiro
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

10.  Bronchodilator and pre-protective effects of urodilatin in bovine bronchi in vitro: comparison with atrial natriuretic peptide.

Authors:  J E Nally; C C Docherty; R A Clayton; N C Thomson
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.